Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer. - PubMed - NCBI

Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer. - PubMed - NCBI

Future Oncol. 2017 Nov 23. doi: 10.2217/fon-2017-0427. [Epub ahead of print]

Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer.

Ribnikar D1, Bedard PL1.

Author information

KEYWORDS:

PAM-50; biomarker; early breast cancer; endocrine therapy; gene expression profiling; late relapse; oncotype DX; prediction

PMID:

 

29168649

 

DOI:

 

10.2217/fon-2017-0427